BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q4 EPS of ($1.01), $0.14 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $12.89 million versus the consensus estimate of $21.58 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.